PE120299A1 - Uso de un antagonista de 5-hidroxitriptamina - Google Patents

Uso de un antagonista de 5-hidroxitriptamina

Info

Publication number
PE120299A1
PE120299A1 PE1998000940A PE00094098A PE120299A1 PE 120299 A1 PE120299 A1 PE 120299A1 PE 1998000940 A PE1998000940 A PE 1998000940A PE 00094098 A PE00094098 A PE 00094098A PE 120299 A1 PE120299 A1 PE 120299A1
Authority
PE
Peru
Prior art keywords
antagonist
hydroxitriptamine
lerisetron
ronetron
discomfortment
Prior art date
Application number
PE1998000940A
Other languages
English (en)
Inventor
Allen Wayne Mangel
Allison Ruth Northcutt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE120299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE120299A1 publication Critical patent/PE120299A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE AL USO DE UN ANTAGONISTA DEL RECEPTOR 5-HIDROXITRIPTAMINA (5-HT3), COMO CLORHIDRATO DE ALOSETRON, GRANISETRON, AZASETRON, TROPISETRON, RAMOSETRON, ONDANSETRON, LERISETRON, (R)-ZACOPRIDA, CILANSETRON, ITASETRON, INDISETRON O DOLASETRON; PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE SINDROME DEL INTESTINO IRRITABLE (IBS) CARACTERIZADO POR EL DOLOR ABDOMINAL Y LAS MOLESTIAS Y LAS FUNCIONES ALTERADAS DEL INTESTINO
PE1998000940A 1997-10-07 1998-10-05 Uso de un antagonista de 5-hidroxitriptamina PE120299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments

Publications (1)

Publication Number Publication Date
PE120299A1 true PE120299A1 (es) 1999-12-15

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000940A PE120299A1 (es) 1997-10-07 1998-10-05 Uso de un antagonista de 5-hidroxitriptamina

Country Status (36)

Country Link
US (3) US6284770B1 (es)
EP (1) EP1021174A2 (es)
JP (1) JP2001518495A (es)
KR (1) KR20010015707A (es)
CN (1) CN1281357A (es)
AP (1) AP2000001785A0 (es)
AR (1) AR017296A1 (es)
AU (1) AU750818B2 (es)
BR (1) BR9812886A (es)
CA (1) CA2305751A1 (es)
CO (1) CO5011096A1 (es)
DZ (1) DZ2618A1 (es)
EA (1) EA003184B1 (es)
EE (1) EE200000214A (es)
GB (1) GB9721139D0 (es)
GT (1) GT199800157A (es)
HN (1) HN1998000155A (es)
HR (1) HRP20000198A2 (es)
HU (1) HUP0003750A3 (es)
ID (1) ID23874A (es)
IL (1) IL135398A0 (es)
IS (1) IS5425A (es)
MA (1) MA26549A1 (es)
NO (1) NO20001776L (es)
NZ (1) NZ503698A (es)
PA (1) PA8461101A1 (es)
PE (1) PE120299A1 (es)
PL (1) PL340337A1 (es)
SK (1) SK4862000A3 (es)
SV (1) SV1998000122A (es)
TN (1) TNSN98179A1 (es)
TR (1) TR200000913T2 (es)
UY (1) UY25200A1 (es)
WO (1) WO1999017755A2 (es)
YU (1) YU20600A (es)
ZA (1) ZA989061B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (en) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Use of (R)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
WO2002020841A2 (en) * 2000-09-06 2002-03-14 Glaxo Group Limited 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
EP1395289B1 (en) * 2001-06-07 2010-12-15 Christine Dr. Sang Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists
US7045549B2 (en) 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
CA2473392A1 (en) * 2002-01-18 2003-07-31 Aryx Therapeutics 5-ht3 receptor antagonists and methods of use
AU2003255712B2 (en) * 2002-07-10 2007-03-15 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-D) pyrimidine in the treatment of functional bowel disorder
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
US20040147510A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
NZ541656A (en) * 2004-01-30 2008-05-30 Astellas Pharma Inc The use of ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
CA2555256A1 (en) * 2004-02-03 2005-08-25 The Regents Of The University Of California Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
JP4912145B2 (ja) * 2004-02-26 2012-04-11 あすか製薬株式会社 ピリミジン誘導体
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
ATE495171T1 (de) * 2005-06-07 2011-01-15 Theravance Inc Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
WO2007000046A1 (en) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methods for diagnosing functional bowel disease
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
CA2642610A1 (en) * 2006-02-20 2007-08-30 Astellas Pharma Inc. Amide derivative or salt thereof
WO2009053750A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline and amorphous forms
WO2009053733A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
WO2009053732A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel salt
WO2009053754A2 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
CN102421891B (zh) 2009-03-04 2015-11-25 生命之叶公司 用于生物分子的位点活化络合的方法与物质
US8568743B2 (en) 2009-04-29 2013-10-29 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
KR20120111954A (ko) * 2009-06-30 2012-10-11 아스텔라스세이야쿠 가부시키가이샤 완해기의 염증성 장질환 환자에서의 배변 이상 치료제
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
HUE030811T2 (hu) * 2011-10-18 2017-05-29 Helsinn Healthcare Sa Netupitant és palonosetron terápiás kombinációi
IN2015DN01706A (es) 2012-09-05 2015-05-22 Chase Pharmaceuticals Corp
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (en) 1986-07-25 1992-10-07 Beecham Group Plc Azabicyclic compounds, process for their preparation, and their pharmaceutical use
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
PH25493A (en) 1987-09-03 1991-07-24 Glaxo Group Ltd 2,3,4,5-tetrahydro-2-£(imidazol-(or-5)-yl)methyl-ih-pyrido£4,3-b|indol-1-ones , derivatives having 5-ht antagonist activity 3
DE3850742T2 (de) 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
US5116984A (en) * 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Imidazole derivatives, process for their preparation and their pharmaceutical use
GB9020927D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
AU1161292A (en) 1991-01-09 1992-08-17 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
HUP0003750A2 (hu) 2001-10-28
EA003184B1 (ru) 2003-02-27
JP2001518495A (ja) 2001-10-16
GB9721139D0 (en) 1997-12-03
KR20010015707A (ko) 2001-02-26
NZ503698A (en) 2002-10-25
NO20001776L (no) 2000-06-06
CN1281357A (zh) 2001-01-24
CO5011096A1 (es) 2001-02-28
HUP0003750A3 (en) 2003-02-28
US20030036549A1 (en) 2003-02-20
PA8461101A1 (es) 2000-05-24
ZA989061B (en) 2001-07-05
US6593336B2 (en) 2003-07-15
AU9629398A (en) 1999-04-27
HN1998000155A (es) 1999-05-24
BR9812886A (pt) 2000-08-08
MA26549A1 (fr) 2004-12-20
US20010044450A1 (en) 2001-11-22
WO1999017755A3 (en) 1999-09-23
AU750818B2 (en) 2002-07-25
IL135398A0 (en) 2001-05-20
WO1999017755A2 (en) 1999-04-15
NO20001776D0 (no) 2000-04-06
DZ2618A1 (fr) 2003-03-01
AR017296A1 (es) 2001-09-05
PL340337A1 (en) 2001-01-29
HRP20000198A2 (en) 2001-04-30
TR200000913T2 (tr) 2001-01-22
IS5425A (is) 2000-03-31
UY25200A1 (es) 2001-01-31
EE200000214A (et) 2001-06-15
US6429209B2 (en) 2002-08-06
GT199800157A (es) 2000-03-30
YU20600A (sh) 2003-10-31
CA2305751A1 (en) 1999-04-15
EP1021174A2 (en) 2000-07-26
ID23874A (id) 2000-05-25
TNSN98179A1 (fr) 2005-03-15
SK4862000A3 (en) 2001-01-18
EA200000299A1 (ru) 2000-12-25
SV1998000122A (es) 1999-07-05
US6284770B1 (en) 2001-09-04
AP2000001785A0 (en) 2000-06-30

Similar Documents

Publication Publication Date Title
PE120299A1 (es) Uso de un antagonista de 5-hidroxitriptamina
ECSP22033597A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
UY26808A1 (es) Compuestos de succinimida heterocíclicos fusionados y análogos de los mismos, modulares de la función del receptor de hormona nuclear
ECSP045203A (es) Cicloalcanindoles con sustitución con flúor y su uso como antagonistas del receptor prostaglandina d2
PA8620501A1 (es) Compuestos utiles en terapia
MX364453B (es) Heterociclos de 5 miembros que contienen nitrógeno sustituido con carboxaminda o sulfonamida como moduladores para el receptor nuclear de orfan ror?.
AR115663A1 (es) Compuestos
ECSP045392A (es) Moduladores tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos de la actividad de receptores de quimiocina
SV2010003687A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
CO6382124A2 (es) Antagonistas del receptor ccr2 y usos de los mismos
CR7574A (es) 3- aminopirazoes triciclicos sustituidos como inhibidores del receptor del factor de crecimiento derivado de plaquetas
DOP2013000044A (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3)
CR10545A (es) Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
ECSP099338A (es) Derivados de quiniclidina de ácido (hetero) arilcicloheptano carboxíclico como antagonistas del receptor muscarínico
PE20231103A1 (es) Compuestos de piperidina sustituida y su uso
CR20180323A (es) Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2015100092A3 (en) 7-beta analogs of orvinols
EA202192093A1 (ru) Пиразолопиридины и триазолопиридины в качестве ингибиторов a2а/a2b
ECSP12011904A (es) Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1.
SI2432467T1 (en) ANTAGONIST RECEPTOR SEROTONINA 5-HT3 FOR THE USE IN THE TREATMENT OF LEASE VESTIBULAR DISEASES
PH12021550048A1 (en) Selective estrogen receptor degraders.
PE20240050A1 (es) Inhibidores de cdk2 y metodos de uso de los mismos
MX2023004366A (es) Composiciones para el tratamiento de la hipertension.
MX2016016299A (es) Formas solidas de un compuesto antiviral.
MA38126B1 (fr) 6-((s)-1-{1-[5-(2-hydroxy-éthoxy)-pyridin-2-yl]-1hpyrazol-3-yl}- éthyl)-3h1,3-benzothiazol-2-one comme antagoniste des récepteurs de l’ampa dépendants de tarp-gamma 8

Legal Events

Date Code Title Description
FC Refusal